Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance

Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance published by Datamonitor in July, 2009. This report consists of 375 pages and the price starts from US $ 15200.

Introduction

Abstract

Introduction

Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Globally, sales for osteoporosis drugs grew 7.0% year-on-year from 2004 to $9.6 billion in 2008 driven by strong performance of the bisphosphonate class.

Scope of this research

• Patient potential analysis across the seven major markets and BRIC nations (Brazil, Russia, India, and China).
• Analysis of global osteoporosis prescriptions from 20042008, split by geographical region, drug class, molecule, and brand.
• In depth profiles of key current osteoporosis brands including SWOT analyses and country-specific sales forecasts to 2018.
• R&D pipeline analysis with detailed profiles and forecasts of key agents, including Amgen' s denosumab and new selective estrogen receptor modulators.

Research and analysis highlights

The osteoporosis seven major market value was $7.1 billion in 2008, 76.4% of the global market. Although between 2007 and 2008 the market declined due to generic penetration of the market leading brand Fosamax (alendronate, Merck & Co), the launch of new pipeline drugs will result in a significant market growth.

The launch of four pipeline selective estrogen receptor modulators (SERMs) between 2009 and 2012 will boost class sales across the seven major markets. However, the challenge for marketing companies is to convince prescribers in the EU, where uptake has historically been low, of the effect of SERMs in the wider patient group.

The largest growth driver of the osteoporosis market over the forecast period is expected to be Amgen' s denosumab, potentially the first monoclonal antibody to market. However, success will rely on a good long-term safety profile and price competitiveness, which are relative unknowns at this stage.

Key reasons to purchase this research

• Understand current and future osteoporosis drug market dynamics
• Gain insight into the unmet needs of current osteoporosis treatment and to what extent pipeline drugs will address these issues
• Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2018 in the US, Japan, France, Germany, Italy, Spain, and the UK

Table of Contents

EXECUTIVE SUMMARY

• Scope of the analysis
• Datamonitor insight into the osteoporosis market
• Key metrics
• Contributing experts
• Related reports

PATIENT POTENTIAL

• Definition of osteoporosis
  • Etiology
  • Symptoms
  • Diagnosis and treatment rates
• Patient segmentation
  • Disease severity
  • Gender
• Epidemiology
  • Seven major markets
  • BRIC countries
  • Rest of the world
• Current treatment options
  • Bisphosphonates
  • Selective estrogen receptor modulators
  • Parathyroid hormones
  • Calcitonins
  • Dual acting bone agents
  • Vitamin D and analogs
  • Calcium
• Clinical unmet need in osteoporosis
  • Need for improved anabolic therapies
  • Efficacy at the hip
  • Increased compliance
  • Better side-effect profile and safety
  • Efficacy for spine fractures
• Environmental unmet need in osteoporosis
  • Increased patient identification
  • Increased prevention of osteoporosis
  • Increase male osteoporosis awareness
  • Target product profile

MARKET OVERVIEW

• Market definition for this report
• Seven major markets current and future market assessment
  • The osteoporosis market will continue to grow up to 2018 despite generic alendronate penetration
• Rest of the world snapshot
  • The global osteoporosis market continues to display strong growth
  • The rest of the world accounted for 25.4% of the osteoporosis global market in 2008
  • The rest of the world outstrips the seven major markets in terms of volume
  • Other European countries form the largest region, but the BRIC countries are by far the fastest-growing
  • Calcium accounts for over 90% of the total volume sales in the rest of the world
• Patient acquisition process
  • Introduction
  • Patient care path
  • Points of influence in the patient care path
  • Drivers of drug choice
• US formulary tier status for leading brands
• EU osteoporosis reimbursement policies
• Brand dynamics - bisphosphonates
  • Class overview
  • Fosamax/Fosamax Plus D (alendronate, Merck & Co.)
  • Actonel/Actonel with Calcium (risedronic acid; Procter and Gamble/Sanofi-Aventis)
  • Bonviva/Boniva (ibandronic acid, Roche/GlaxoSmithKline)
  • Aclasta (zoledronic acid, Novartis)
  • Bonoteo/Recalbon (minodronic acid, Astellas/Ono Pharmaceutical)
  • Brand dynamics - selective estrogen receptor modulators
  • Evista (raloxifene, Eli Lilly)
• Brand dynamics - parathyroid hormones
  • Forteo (teriparatide, Eli Lilly)
  • Preotact (full-length parathyroid hormone PTH 1-84, NPS/Nycomed)
• Brand dynamics - dual acting bone agents
  • Protelos (strontium ranelate, Servier)
• Brand dynamics - calcitonins
  • Miacalcic (calcitonin-salmon, Novartis)
  • Fortical (calcitonin-salmon, Unigene)

PIPELINE OVERVIEW AND R&D DYNAMICS

• Pipeline overview
  • Comparative forecasts
  • Datamonitor pipeline assessment summary
• Key companies involved in the disease osteoporosis pipeline
  • Companies currently involved in the market are seeking novel drug developments to maintain their market share
  • Amgen - a future key market player
• Clinical trial design in osteoporosis
  • Preclinical trials

LATE-STAGE DRUG ANALYSIS AND FORECASTS

• Definition of current comparator therapies
  • Overall market comparator - Fosamax (alendronate, Merck & Co)
  • Individual class comparators
• Bisphosphonates - key late-stage pipeline
  • Pipeline summary
  • Comparative forecasts
  • EX101 (alendronate; EffRx)
  • Almerol (MER-103, alendronate; Merrion)
  • Late-stage development compounds recently discontinued
• Selective estrogen receptor modulators - key late-stage pipeline
  • Pipeline summary
  • Comparative forecasts
  • Fablyn (lasofoxifene; Pfizer/Ligand)
  • Conbriza/Viviant (bazedoxifene; Wyeth)
  • Aprela (bazedoxifene with conjugated estrogens; Wyeth)
  • Arzoxifene (LY353381, Eli Lilly)
• Parathyroid hormones and analogs - key late-stage pipeline
  • Pipeline summary
  • Comparative forecasts
  • ZT-031 (previously Ostabolin-C, Zelos Therapeutics)
  • ZP-PTH (hPTH1-34, Zosano Pharma)
• Calcitonins - key late-stage pipeline
  • Pipeline summary
  • Capsitonin (BN-002, Bone medical)
  • Drug overview
• Other drugs - key late-stage pipeline
  • Pipeline summary
  • Comparative forecasts
  • Denosumab (AMG-162, Amgen)
  • Odanacatib (MK0822, Merck & Co)
  • Eldecalcitol (ED-71, Chugai/Taisho)
• Key early-stage compounds in osteoporosis

BIBLIOGRAPHY

• Journal papers, books, and conference abstracts
• Websites
• Datamonitor reports

APPENDIX A

• Data definitions, limitations and assumptions
  • Standard units
  • Derivation of sales forecasts and pricing trends
• Methodology
  • Indication-specific sales calculations

APPENDIX B

• Contributing experts

TABLES

• Table: Sales forecast for key marketed brands in osteoporosis across the seven major markets, 2008 - 2018
• Table: Sales forecast for pipeline products in osteoporosis in the seven major markets ($m), 2009 - 2018
• Table: Risk factors (-) and protective factors (+) for axial and appendicular bone mineral density in women aged 65 years and over
• Table: Fracture risk assessment tool (FRAX) questionnaire, 2009
• Table: 10-year probability of osteoporotic fractures (%), according to BMD T-score at the femoral neck in women aged 65 years from the UK n
• Table: Causes of male osteoporosis
• Table: Summary of osteoporosis prevalence studies in the seven major markets, 2009
• Table: Osteopenia epidemiology across the seven major markets, 2009
• Table: Osteoporosis epidemiology across the seven major markets, 2009
• Table: Severe osteoporosis epidemiology across the seven major markets, 2009
• Table: Summary of osteoporosis epidemiology of women over 50 years of age across the seven major markets, 2009
• Table: Estimated osteoporosis epidemiology of women over 50 years of age across the seven major markets, 2020
• Table: Prevalence of osteopenia in men over 50 across the seven major markets, 2009
• Table: Prevalence of osteoporosis in men over 50 across the seven major markets, 2009
• Table: Estimated female hip fracture prevalence in Brazil, 2009, 2015 and 2020
• Table: Estimated male hip fracture prevalence in Brazil, 2009, 2015 and 2020
• Table: Estimated number of female hip fractures in Russia, North America and Europe, 1990, 2025, and 2050
• Table: Estimated number of male hip fractures in Russia, North America, Europe, 1990, 2025 and 2050
• Table: Female prevalence of osteopenia in India, 2009, 2015 and 2020
• Table: Female prevalence of osteoporosis in India, 2009, 2015 and 2020
• Table: Estimated number of hip fractures in Chinese women, 2009, 2015 and 2020
• Table: Estimated female osteoporosis prevalence in China, 2009, 2015, 2020
• Table: Estimated male osteoporosis prevalence in China, 2009, 2015, 2020
• Table: Estimated number of osteoporotic fractures by site, in men and women aged 50 years and over by region, in 2000
• Table: Key medications currently approved for osteoporosis treatment across the seven major markets, 2009
• Table: Key marketed bisphosphonates in osteoporosis across the seven major markets, 2009
• Table: Marketed selective estrogen receptor modulators in osteoporosis across the seven major markets, 2009
• Table: Marketed parathyroid hormones in osteoporosis, 2009
• Table: Key marketed calcitonins in osteoporosis across the seven major markets, 2009
• Table: Key dual acting bone agents marketed across the seven major markets, 2009
• Table: Summary of key drugs in osteoporosis side effects and safety profiles, 2009
• Table: Osteoporosis target product profile, 2009
• Table: Summary of therapeutic classes in osteoporosis by ATC code, 2009
• Table: Summary of the ICD-10 codes used to derive osteoporosis-specific sales from each brand
• Table: Regional osteoporosis market sales ($m) dynamics across the seven major markets, 2004 - 2018
• Table: ATC class sales ($m) in osteoporosis across the seven major markets , 2004 - 2018
• Table: Key marketed brand sales ($m) in osteoporosis across the seven major markets, 2004 - 08
• Table: Sales forecast for key marketed brands in osteoporosis across the seven major markets, 2008 - 2018
• Table: Key events impacting the osteoporosis market, 2009 - 2018
• Table: Global sales ($m) dynamics of the osteoporosis market, 2004 - 08
• Table: Regional split of the global osteoporosis market sales, 2004 - 08
• Table: Global osteoporosis market volume (IMS standard unit) sales by ATC class, 2008
• Table: Representative formulary tier status in the US for leading brands in osteoporosis, 2009
• Table: EU osteoporosis treatment reimbursement policies, 2008
• Table: Fosamax: key facts, 2009
• Table: Impacting factors on the revenues of Fosamax brand franchise, 2009 - 2018
• Table: Actonel: key facts, 2009
• Table: Impacting factors on the revenues of the Actonel brand franchise, 2009 - 2018
• Table: Bonviva: key facts, 2009
• Table: Impacting factors on the revenues of Bonviva brand franchise, 2009 - 2018
• Table: Aclasta: key facts, 2009
• Table: Impacting factors on the revenues of Aclasta, 2009 - 2018
• Table: Bonoteo: key facts, 2009
• Table: Impacting factors on the revenues of Bonoteo, 2009 - 2018
• Table: Evista: key facts, 2009
• Table: Impacting factors on the revenues of Evista, 2009 - 2018
• Table: Forteo: key facts, 2009
• Table: Impacting factors on the revenues of Forteo, 2009 - 2018
• Table: Preotact: key facts, 2009
• Table: Impacting factors on the revenues of Preotact, 2009 - 2018
• Table: Protelos: key facts, 2009
• Table: Impacting factors on the revenues of Protelos , 2009 - 2018
• Table: Miacalcic: key facts, 2009
• Table: Impacting factors on the revenues of Miacalcic , 2009 - 2018
• Table: Fortical: key facts, 2009
• Table: Impacting factors on the revenues of Fortical, 2009 - 2018
• Table: R&D drug pipeline for osteoporosis, 2009
• Table: Sales forecast for pipeline products in osteoporosis in the seven major markets ($m), 2009 - 2018
• Table: Amgen' s osteoporosis pipeline, 2009
• Table: FDA and EMEA preclinical study requirements for osteoporosis drug approval, 2009
• Table: Summary of the key FDA and EMEA Phase III clinical trial requirements in osteoporosis, 2009
• Table: FDA recommended primary efficacy points for prevention and treatment studies
• Table: Biomarkers for bone formation and bone resorption, 2009
• Table: Defining the gold standard for osteoporosis: key clinical trial results for Fosamax
• Table: Key efficacy data for Fosamax (alendronate), Evista (raloxifene) Forteo (teriparatide) and Miacalcic (calcitonin-salmon) in the treatment of osteoporosis
• Table: Key products in the late-stage bisphosphonate pipeline for osteoporosis, 2009
• Table: EX101: key facts, 2009
• Table: Sales forecasts ($m) for EX101 in the seven major markets, 2011 - 18
• Table: Impacting factors on the revenues of EX101, 2011 - 18
• Table: Almerol: key facts, 2009
• Table: Sales ($m) forecasts for Almerol in the seven major markets, 2014 - 18
• Table: Impacting factors on the revenues of Almerol, 2014 - 18
• Table: Recently discontinued late-stage bisphosphonates, 2009
• Table: Key products in the late-stage selective estrogen receptor modulator (SERM) pipeline for osteoporosis, 2009
• Table: Fablyn: key facts, 2009
• Table: Summary of key Phase III clinical trials for Fablyn (lasofoxifene)
• Table: Cumulative outcomes of 3 years treatment with Fablyn (lasofoxifene) versus placebo (rate per 1,000 subjects over 3 years)
• Table: Sales ($m) forecasts for Fablyn in the seven major markets, 2010 - 18
• Table: Impacting factors on the revenues of Fablyn, 2010 - 18
• Table: Conbriza: key facts, 2009
• Table: Summary of key Phase III clinical trials for Conbriza (bazedoxifene)
• Table: Summary of fracture data from Conbriza (bazedoxifene) Phase III clinical trial
• Table: Sales forecasts for Conbriza in the seven major markets, 2009 - 2018 ($m)
• Table: Impacting factors on the revenues of Conbriza, 2009 - 2018
• Table: Aprela: key facts, 2009
• Table: Aprela forecast osteoporosis sales ($m) across the seven major markets, 2011 - 2018
• Table: Impacting factors on the revenues of Aprela, 2011 - 18
• Table: Arzoxifene: key facts, 2009
• Table: Summary of key clinical trials for arzoxifene
• Table: Arzoxifene Phase III study results, 2009
• Table: Phase III trial in postmenopausal women to determine the efficacy of arzoxifene on fracture risk and breast cancer, 2009
• Table: Arzoxifene forecast osteoporosis sales ($m) across the seven major markets, 2012 - 2018
• Table: Impacting factors on the revenues of arzoxifene, 2012 - 18
• Table: Key products in the late-stage parathyroid hormone (PTH) pipeline for osteoporosis, 2009
• Table: ZT-031: key facts, 2009
• Table: ZT-031 forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
• Table: Impacting factors on the revenues of ZT-031, 2014 - 18
• Table: ZP-PTH: key facts, 2009
• Table: ZP-PTH forecast osteoporosis sales ($m) across the seven major markets, 2015 - 18
• Table: Impacting factors on the revenues of ZP-PTH, 2015 - 18
• Table: Key products in the late-stage calcitonin pipeline for osteoporosis, 2009
• Table: Capsitonin: key facts, 2009
• Table: Capsitonin forecast osteoporosis sales ($m) across the seven major markets, 2013 - 18
• Table: Impacting factors on the revenues of capsitonin, 2013 - 18
• Table: Key products in the late-stage ' other treatments' pipeline for osteoporosis, 2009
• Table: Denosumab: key facts, 2009
• Table: Summary of key denosumab studies, 2009
• Table: Denosumab Phase III DECIDE clinical trial results
• Table: Japanese Phase III trial in postmenopausal women to determine the efficacy of denosumab in reducing fracture risk, 2009
• Table: Denosumab forecast osteoporosis sales ($m) across the seven major markets, 2010 - 18
• Table: Impacting factors on the revenues of denosumab, 2010 - 18
• Table: Odanacatib: key facts, 2009
• Table: Phase III trial in postmenopausal women to determine the efficacy of odanacatib in reducing fracture risk, 2009
• Table: Phase III trial in postmenopausal women to determine the efficacy of odanacatib on bone mineral density (BMD), 2009
• Table: Phase III trial in postmenopausal women to determine the safety and efficacy of odanacatib on bone mineral density (BMD), 2009
• Table: Odanacatib forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
• Table: Impacting factors on the revenues of odanacatib, 2014 - 18
• Table: Eldecalcitol: key facts, 2009
• Table: Summary of key clinical trials for eldecalcitol
• Table: Eldecalcitol forecast osteoporosis sales ($m) across the seven major markets, 2011 - 18
• Table: Impacting factors on the revenues of eldecalcitol, 2011 - 18
• Table: Summary of products in preclinical trials for the treatment of osteoporosis, 2009
• Table: Patent expiry dates for key marketed brands in osteoporosis in the US and Japan, 2009
• Table: Patent expiry dates for key marketed brands in osteoporosis in the five major European market regions, 2009
• Table: Estimated launch dates for key late stage pipeline products and marketed brands in the seven major market regions, 2009 - 2018
• Table: Datamonitor drug assessment parameters for pipeline bisphosphonate products, 2009
• Table: Datamonitor drug assessment parameters for pipeline selective estrogen receptor modulators (SERMs) products, 2009
• Table: Datamonitor drug assessment parameters for pipeline parathyroid hormone (PTH) products, 2009
• Table: Datamonitor drug assessment parameters for pipeline calcitonins products, 2009
• Table: Datamonitor drug assessment parameters for pipeline other products, 2009

FIGURES

• Figure: Development of osteoporotic bone
• Figure: Osteoporotic fractures occur most commonly at the spine, hip and wrist
• Figure: Potentially osteoporotic patients who receive each method of additional diagnostic technique, 2008
• Figure: Treatment of Caucasian women aged 60 years or older with osteoporosis or vertebral fractures by primary care physicians, by drug type, 1993 - 97
• Figure: World Health Organization classification of osteoporotic bone loss
• Figure: Average prevalence according to osteoporosis severity across the seven major markets, 2008
• Figure: Female osteoporosis epidemiology by severity of women across the seven major markets, 2009
• Figure: Increase of osteoporosis prevalence by severity, 2009 - 2020
• Figure: Hip fracture prevalence across the BRIC countries, 2009 - 2020
• Figure: Estimated number of male hip fractures in Russia, North America, Europe, 1990, 2025 and 2050
• Figure: Bisphosphonate mechanism of action
• Figure: Selective estrogen receptor modulator' s mechanism of action in osteoporosis, 2009
• Figure: Key clinical unmet needs in osteoporosis, 2009
• Figure: Percentage of patients discontinuing pharmacological treatment due to non-compliance at different times across the seven major markets, 2008
• Figure: Key environmental unmet needs in osteoporosis, 2009
• Figure: Osteoporosis market sales ($m) across the seven major markets, 2004 - 2018
• Figure: Osteoporosis market sales dynamics ($m) across the seven major markets, 2004 - 2018
• Figure: Osteoporosis market volume sales (IMS standard units) across the seven major markets, 2004 - 08
• Figure: Regional osteoporosis market value sales ($m) in the across the seven major markets, 2004 - 08
• Figure: Forecast regional osteoporosis market value sales ($m) across the seven major markets, 2008 - 2018
• Figure: Regional osteoporosis market volume sales (IMS standard units sold) across the seven major markets, 2004 - 08
• Figure: Forecast regional osteoporosis market volume sales (IMS standard units sold) across the seven major markets, 2008 - 2018
• Figure: ATC class sales ($m) in osteoporosis across the seven major markets, 2004 - 08
• Figure: ATC class sales ($m) in osteoporosis across the seven major markets, 2008 - 2018
• Figure: Key marketed brand sales ($m) dynamics in osteoporosis across the seven major markets, 2004 - 08
• Figure: Global osteoporosis market sales ($m), 2004 - 08
• Figure: Global osteoporosis market sales ($m) dynamics, 2004 - 08
• Figure: Global osteoporosis market volume (IMS standard units sold) and value ($) sales, 2008
• Figure: Rest of the world osteoporosis market sales value ($m), 2004 - 08
• Figure: Rest of the world osteoporosis market regional dynamics, 2004 - 08
• Figure: Rest of the world osteoporosis market ATC class dynamics, 2004 - 08
• Figure: Osteoporosis patient care path in the seven major markets, 2009
• Figure: Key drivers of drug choice in osteoporosis across the seven major markets, 2008
• Figure: Assessment of formulary status in osteoporosis in the US, 2009
• Figure: Overall Fosamax branded franchise sales ($m) in osteoporosis across the seven major markets, 2004 - 08
• Figure: Fosamax franchise: SWOT analysis, 2009
• Figure: Fosamax brand franchise osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
• Figure: Fosamax Plus D osteoporosis sales ($m) across the seven major markets, 2004 - 2018
• Figure: Actonel branded franchise sales ($m) in osteoporosis across the seven major markets, 2004 - 08
• Figure: Actonel franchise: SWOT analysis, 2009
• Figure: Actonel brand franchise osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
• Figure: Actonel and Actonel with Calcium osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
• Figure: Bonviva branded franchise market sales ($m) in osteoporosis across the seven major markets, 2004 - 08
• Figure: Bonviva franchise: SWOT analysis, 2009
• Figure: Bonviva brand franchise osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
• Figure: Bonviva oral and intravenous (IV) osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
• Figure: Aclasta market sales ($m) in osteoporosis across the seven major markets, 2006 - 08
• Figure: Aclasta: SWOT analysis, 2009
• Figure: Aclasta forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
• Figure: Bonoteo: SWOT analysis, 2009
• Figure: Bonoteo forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
• Figure: Evista' s sales dynamics in osteoporosis across the seven major markets, 2005 - 08
• Figure: Evista: SWOT analysis, 2009
• Figure: Evista forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
• Figure: Evista' s regional osteoporosis sales ($m) across the seven major markets, 2004 - 2018
• Figure: Forteo' s sales in osteoporosis across the seven major markets, 2004 - 08
• Figure: Forteo: SWOT analysis, 2009
• Figure: Forteo forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
• Figure: Forteo regional osteoporosis sales ($m) across the seven major markets, 2004 - 2018
• Figure: Preotact' s sales in osteoporosis across the seven major markets, 2006 - 08
• Figure: Preotact: SWOT analysis, 2009
• Figure: Preotact forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
• Figure: Preotact regional osteoporosis sales ($m) across the seven major markets, 2007 - 2018
• Figure: Protelos sales ($m) in osteoporosis across the seven major markets, 2005 - 08
• Figure: Protelos: SWOT analysis, 2009
• Figure: Protelos forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
• Figure: Protelos regional osteoporosis sales ($m) across the seven major markets, 2005 - 2018
• Figure: Miacalcic sales ($m) in osteoporosis across the seven major markets, 2004 - 08
• Figure: Miacalcic: SWOT analysis, 2009
• Figure: Miacalcic franchise forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
• Figure: Fortical sales ($m) in osteoporosis across the seven major markets, 2004 - 08
• Figure: Fortical: SWOT analysis, 2009
• Figure: Fortical forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
• Figure: Pipeline drugs for osteoporosis by development phase, 2009
• Figure: Pipeline drugs for osteoporosis by class, 2009
• Figure: Pipeline drugs for osteoporosis by development phase and class of drug, 2009
• Figure: Pipeline drugs for osteoporosis by mechanism of action, 2009
• Figure: Datamonitor drug assessment summary of pipeline bisphosphonates for osteoporosis, 2009
• Figure: Datamonitor drug assessment summary of pipeline selective estrogen receptor modulator (SERM) treatments for osteoporosis, 2009
• Figure: Datamonitor drug assessment summary of pipeline parathyroid hormone (PTH) treatments for osteoporosis, 2009
• Figure: Datamonitor drug assessment summary of pipeline calcitonin treatments for osteoporosis, 2009
• Figure: Datamonitor drug assessment summary of other pipeline treatments for osteoporosis, 2009
• Figure: Guide to the Food and Drug Administration (FDA) action on new drug applications for osteoporosis
• Figure: Datamonitor drug assessment summary of bisphosphonate treatments for osteoporosis, 2009
• Figure: Sales ($m) forecast for key pipeline drugs for osteoporosis bisphosphonates in the seven major markets, 2008 - 2018
• Figure: EX101: SWOT analysis, 2009
• Figure: Datamonitor drug assessment summary of EX101 for osteoporosis, 2009
• Figure: EX101 forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
• Figure: Almerol: SWOT analysis, 2009
• Figure: Datamonitor drug assessment summary of Almerol for osteoporosis, 2009
• Figure: Almerol forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
• Figure: Datamonitor drug assessment summary of selective estrogen receptor modulators (SERMs) treatments for osteoporosis, 2009
• Figure: Sales ($m) forecast for key pipeline drugs for osteoporosis selective estrogen receptor modulators (SERM) in the seven major markets, 2008 - 2018
• Figure: Fablyn: SWOT analysis, 2009
• Figure: Postmenopausal evaluation and risk-reduction with lasofoxifene (PEARL) clinical trial design
• Figure: Datamonitor drug assessment summary of Fablyn for osteoporosis, 2009
• Figure: Fablyn forecast osteoporosis sales ($m) across the seven major markets, 2009 - 2018
• Figure: Conbriza: SWOT analysis, 2009
• Figure: Conbriza (bazedoxifene) clinical trial design and results
• Figure: Conbriza (bazedoxifene) Phase III clinical trial design
• Figure: Datamonitor drug assessment summary of Conbriza for osteoporosis, 2009
• Figure: Conbriza forecast osteoporosis sales ($m) across the seven major markets, 2009 - 2018
• Figure: Aprela: SWOT analysis, 2009
• Figure: Datamonitor drug assessment summary of Aprela for osteoporosis, 2009
• Figure: Aprela forecast osteoporosis sales ($m) across the seven major markets, 2011 - 2018
• Figure: Arzoxifene: SWOT analysis, 2009
• Figure: Datamonitor drug assessment summary of arzoxifene for osteoporosis, 2009
• Figure: Arzoxifene forecast osteoporosis sales ($m) across the seven major markets, 2011 - 2018
• Figure: Datamonitor drug assessment summary of parathyroid hormone (PTH) treatments for osteoporosis, 2009
• Figure: Sales ($m) forecast for key pipeline drugs for osteoporosis parathyroid hormone (PTH) in the seven major markets, 2008 - 2018
• Figure: ZT-031: SWOT analysis, 2009
• Figure: Datamonitor drug assessment summary of ZT-031 for osteoporosis, 2009
• Figure: ZT-031 forecast osteoporosis sales ($m) across the seven major markets, 2013 - 18
• Figure: ZP-PTH: SWOT analysis, 2009
• Figure: Datamonitor drug assessment summary of ZP-PTH for osteoporosis, 2009
• Figure: ZP-PTH forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
• Figure: Datamonitor drug assessment summary of calcitonins treatments for osteoporosis, 2009
• Figure: Capsitonin: SWOT analysis, 2009
• Figure: Datamonitor drug assessment summary of capsitonin for osteoporosis, 2009
• Figure: Capsitonin forecast osteoporosis sales ($m) across the seven major markets, 2013 - 18
• Figure: Datamonitor drug assessment summary of other treatments for osteoporosis, 2009
• Figure: Sales ($m) forecast for key pipeline drugs for other osteoporosis treatments in the seven major markets, 2008 - 2018
• Figure: Denosumab: SWOT analysis, 2009
• Figure: Denosumab Phase III DECIDE clinical trial design
• Figure: Datamonitor drug assessment summary of denosumab for osteoporosis, 2009
• Figure: Denosumab forecast osteoporosis sales ($m) across the seven major markets, 2010 - 18
• Figure: Odanacatib: SWOT analysis, 2009
• Figure: Datamonitor drug assessment summary of odanacatib for osteoporosis, 2009
• Figure: Odanacatib forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
• Figure: Eldecalcitol: SWOT analysis, 2009
• Figure: Datamonitor drug assessment summary of eldecalcitol for osteoporosis, 2009
• Figure: Eldecalcitol forecast osteoporosis sales ($m) across the seven major markets, 2011 - 18
• Figure: Datamonitor drug assessment summary of other treatments for osteoporosis, 2009

Related Reports